Statement: The two groups in the primary trial receive the same drug treatment, but different doses.
Primary_evidence: INTERVENTION 1:    AZD8931 160 mg bd   Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2:    AZD8931 120 mg bd   Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle